Drug intelligence / Profile preview

KINE-201B

Development stage: Preclinical
Lead developer: Kine Sciences
Modality: Peptides

Overview

KINE-201B is a peptide-based therapeutic candidate being developed by Kine Science for the treatment of asthma. It is designed to modulate Th2 (Type 2 helper T cell) activity, which is a central driver of allergic and inflammatory responses in the respiratory tract. By targeting the Th2 pathway, KINE-201B aims to regulate the production of pro-inflammatory cytokines that contribute to airway hyperresponsiveness and mucus overproduction. As of the current pipeline information, the asset is in the discovery stage, focusing on the modulation of allergic and inflammatory disease pathways.

Targets

TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on KINE-201B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-201B.

Explore the full profile